NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.50 Average PT from Analysts

Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have received an average rating of "Moderate Buy" from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $14.50.

A number of equities research analysts have weighed in on NPCE shares. Wells Fargo & Company reduced their price objective on NeuroPace from $15.00 to $13.00 and set an "overweight" rating for the company in a research note on Wednesday, November 13th. JPMorgan Chase & Co. lifted their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a report on Tuesday.

NeuroPace Stock Up 3.5 %

NASDAQ NPCE traded up $0.39 during trading on Friday, reaching $11.53. 188,294 shares of the company's stock were exchanged, compared to its average volume of 95,864. The company has a 50 day moving average price of $8.81 and a two-hundred day moving average price of $7.71. The stock has a market cap of $344.15 million, a P/E ratio of -11.53 and a beta of 2.05. NeuroPace has a 1 year low of $5.45 and a 1 year high of $18.15. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.07. The firm had revenue of $21.06 million during the quarter, compared to analysts' expectations of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same quarter in the previous year, the business earned ($0.28) earnings per share. On average, equities research analysts anticipate that NeuroPace will post -1 EPS for the current fiscal year.

Insider Transactions at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 4,031 shares of the business's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74. Following the transaction, the insider now owns 5,521,874 shares in the company, valued at approximately $36,113,055.96. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 257,590 shares of company stock worth $1,437,916 over the last 90 days. 22.20% of the stock is currently owned by insiders.

Institutional Trading of NeuroPace

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers purchased a new position in NeuroPace in the 2nd quarter valued at approximately $111,000. Financial Advocates Investment Management increased its position in shares of NeuroPace by 50.0% in the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company's stock valued at $113,000 after buying an additional 5,000 shares in the last quarter. Barclays PLC increased its position in shares of NeuroPace by 346.0% in the third quarter. Barclays PLC now owns 20,633 shares of the company's stock valued at $144,000 after buying an additional 16,007 shares in the last quarter. XTX Topco Ltd raised its stake in shares of NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company's stock worth $182,000 after buying an additional 8,643 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of NeuroPace in the 2nd quarter worth about $257,000. Institutional investors and hedge funds own 78.83% of the company's stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.